Skip to main content

Table 2 Summary statistics of clinical and laboratory outcome parameters at baseline and after w6, w12, w24 and w52

From: Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFα therapy

Clinical outcome parameters N Median (min–max, IQR) p-value
DAS28 (CRP)
 Baseline 28 4.61 (2.65–6.49, 1.76)  
 w6 28 3.80 (1.49–6.60, 1.88) 0.002
 w12 27 3.26 (1.39–6.65, 2.04) < 0.001
 w24 27 3.20 (1.27–6.37, 1.81) 0.001
 w52 18 2.73 (1.22–4.85, 2.06) < 0.001
Tender Joint Count-28
 Baseline 28 7.00 (0–22, 8.75)  
 w6 28 3.00 (0–22, 7.00) 0.009
 w12 28 4.00 (0–21, 5.00) < 0.001
 w24 27 3.00 (0–17, 4.00) 0.001
 w52 18 2.00 (0–15, 3.50) 0.004
Swollen Joint Count-28
 Baseline 28 2.50 (0–9, 4.00)  
 w6 28 2.00 (0–6, 2.00) 0.052
 w12 28 1.00 ((0–7, 3.00) 0.009
 w24 27 0.00 (0–6, 2.00) 0.005
 w52 18 0.00 (0–6, 1.75) 0.012
CRP (mg/l)
 Baseline 28 5.40 (0.30–52.00, 17.36)  
 w6 27 4.00 (0.30–61.87, 11.85) 0.687
 w12 26 3.25 (0.30–28.90, 6.95) 0.091
 w24 25 2.30 (0.30–41.40, 5.50) 0.028
 w52 18 2.00 (0.20–98.70, 5.02) 0.156
ESR (mm/h)
 Baseline 28 27 (8–66, 21,00)  
 w6 28 20 (4–52, 24,50 0.027
 w12 28 18 (6–56, 23.25) 0.059
 w24 27 21 (2–70, 25.50) 0.203
 w52 18 18 (2–54, 20.00) 0.177
VAS (0–10 cm) patient
 Baseline 28 6.00 (2.40–10.00, 3.00)  
 w6 28 2.90 (0.00–8.50, 3.95) 0.003
 w12 28 4.20 (0.10–8.90, 3.00) 0.003
 w24 27 5.00 (0.30–9.00, 3.70) 0.112
 w52 18 2.95 (0–8.00, 3.63) 0.002
VAS (0–10 cm) physician
 Baseline 28 4.00 (1.9–8.50, 1.70)  
 w6 28 3.00 (1.0–7.50, 2.00) 0.002
 w12 28 2.25 (1.0–8.00, 1.63) 0.001
 w24 27 2.00 (0.5–10.00, 2.25) 0.066
 w52 18 1.50 (0.0–6.00, 2.00) 0.014
Morning stiffness (min.)
 Baseline 28 30.00 (0–240, 63,75)  
 w6 28 2.50 (0–120, 30.00)) 0.003
 w12 28 7.50 (0–90, 33.75) 0.025
 w24 27 0.00 (0–120, 45.00) 0.042
 w52 18 0.00 (0–150, 12.50) 0.091
  1. IQR interquartile range, DAS28 disease activity score of 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, VAS visual analogue scale; significance level of p < 0.05
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us